Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis

Perelas Apostolos; Glennie Jessica; van Kerkhove Karen; Li Manshi; Scheraga Rachel G.; Olman Mitchell A.; Culver Daniel A.

首页> 外文期刊>Pulmonary pharmacology & therapeutics >Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis

【24h】

Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis

机译：抗灰度药物和疾病严重程度的选择预测特发性肺纤维化的体重减轻

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Although safety and tolerability of approved antifibrotics has been reported extensively, little is known about their effects on weight. We analyzed predictors of weight change after one year of uninterrupted antifibrotic therapy in patients followed at our institution's interstitial lung disease clinic.

机译：目的：虽然已经广泛地报告了批准的抗冻剂的安全性和可耐受性，但对其重量的影响很少。我们分析了一年后患者一年不间断的抗纤维化治疗后的重量变化的预测因素，随后在我们的机构的间质性肺病诊所。

著录项

来源
《Pulmonary pharmacology & therapeutics》 |2019年第2019期|共3页
作者
Perelas Apostolos; Glennie Jessica; van Kerkhove Karen; Li Manshi; Scheraga Rachel G.; Olman Mitchell A.; Culver Daniel A.;
展开▼
作者单位

Cleveland Clin Fdn Resp Inst 9500 Euclid Ave Cleveland OH 44195 USA;

Cleveland Clin Fdn Resp Inst 9500 Euclid Ave Cleveland OH 44195 USA;

Cleveland Clin Fdn Resp Inst 9500 Euclid Ave Cleveland OH 44195 USA;

Cleveland Clin Fdn Quantitat Hlth Sci Dept 9500 Euclid Ave Cleveland OH 44195 USA;

Cleveland Clin Fdn Resp Inst 9500 Euclid Ave Cleveland OH 44195 USA;

Cleveland Clin Fdn Resp Inst 9500 Euclid Ave Cleveland OH 44195 USA;

Cleveland Clin Fdn Resp Inst 9500 Euclid Ave Cleveland OH 44195 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词
Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; Weight loss; Body mass index;

机译：特发性肺纤维化;nintedanib;pirefenidone;减肥;体重指数;

相似文献

外文文献
中文文献
专利

1. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis [J] . Perelas Apostolos, Glennie Jessica, van Kerkhove Karen, Pulmonary pharmacology & therapeutics . 2019,第期

机译：抗灰度药物和疾病严重程度的选择预测特发性肺纤维化的体重减轻
2. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study [J] . Mitra Corral, Kathryn DeYoung, Amanda M. Kong BMC Pulmonary Medicine . 2020,第1期

机译：在美国商业和医疗保险补充索赔数据库中抗纤维化药物治疗特发性肺纤维化患者治疗模式，医疗资源利用率和成本：回顾性队列研究
3. CLINICAL FRAILTY SCORE BUT NOT AGE IS ASSOCIATED WITH EARLY TREATMENT DISCONTINUATION WITH ANTIFIBROTIC MEDICATION IN IDIOPATHIC PULMONARY FIBROSIS [J] . Davies S., Holt A., Sutcliffe J., Thorax: The Journal of the British Thoracic Society . 2017,第Suppla3期

机译：临床脆弱分数但没有年龄与早期治疗中断与特发性肺纤维化中的抗纤维化药物中断相关
4. U-radiomics for predicting survival of patients with idiopathic pulmonary fibrosis [C] . Tomoki Uemura, Chinatsu Watari, Janne J.Naeppi, Medical Imaging Conference . 2020

机译：U放射组学可预测特发性肺纤维化患者的生存
5. Correlation of Vascular Leak Measured Using Gadofosveset-Enhanced Lung Magnetic Resonance Imaging with Radiographic and Physiologic Measures of Fibrosis in Patients with Idiopathic Pulmonary Fibrosis. [D] . Liang, Lloyd. 2018

机译：特发性肺纤维化患者使用Gadofosveset增强肺磁共振成像测得的血管渗漏与纤维化的放射学和生理学指标的相关性。
6. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study [O] . Keiji Oishi, Tsunahiko Hirano, Yoriyuki Murata, 2019

机译：特发性肺纤维化患者的药物持续治疗率和停用抗纤维化药物的预测因素：一项现实世界的观察性研究
7. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis [O] . Apostolos Perelas, Jessica Glennie, Karen van Kerkhove, 2019

机译：抗灰度药物和疾病严重程度的选择预测特发性肺纤维化的体重减轻

Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis

摘要

著录项

相似文献

相关主题

期刊订阅